Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension

Hypertension Research

Volumn 30, Issue 8, 2007, Pages 691-697

  Tanaka, Toshinari ^a   Tsutamoto, Takayoshi ^a   Sakai, Hiroshi ^a   Fujii, Masanori ^a   Yamamoto, Takashi ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Aldosterone; Amlodipine; Efonidipine; Heart failure; Hypertension

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NORADRENALIN; RENIN; SPIRONOLACTONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE VARIABILITY; HUMAN; MALE; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ALDOSTERONE; AMLODIPINE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; DIHYDROPYRIDINES; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NITROPHENOLS; NOREPINEPHRINE; ORGANOPHOSPHORUS COMPOUNDS;

EID: 34948896521     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.691     Document Type: Article

References (40)

1. Minami J, Ishimitsu T, Kawano Y, Matsuoka H: Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998; 25: 572-576.
2. Tsutamoto T, Tsutsui T, Maeda K, et al: Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine. J Cardiovasc Pharmacol 2003; 41 (Suppl 1): S77-S81.
3. McKelvie RS, Yusuf S, Pericak D, et al, The RESOLVD Pilot Study Investigators: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999; 100: 1056-1064.
4. Krum H, Nolly H, Workman D, et al: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
5. Tsutamoto T, Wada A, Maeda K, et al: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 37: 1228-1233.
6. Weber KT: Cardioreparation in hypertensive heart disease. Hypertension 2001; 38: 588-591.
7. Vasan RS, Evans JC, Benjamin EJ, et al: Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004; 43: 957-962.
8. Brunner HR, Laragh JH, Baer L, et al: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449.
9. Swedberg K, Eneroth P, Kjekshus J, Snapinn S, CONSENSUS Trial Study Group: Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol 1990; 66: 40D-45D.
10. Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R: Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-1309.
11. + and atrial natriuretic peptide. Am J Physiol 1991; 261: F706-F719.
12. Rossier MF, Burnay MM, Vallotton MB, Capponi AM: Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells. Endocrinology 1996; 137: 4817-4826.
13. Rossier MF, Ertel EA, Vallotton MB, Capponi AM: Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cells. J Pharmacol Exp Ther 1998; 287: 824-831.
14. +. Am J Physiol 1999; 276: F674-F683.
15. Lesouhaitier O, Chiappe A, Rossier MF: Aldosterone increases T-type calcium currents in human adrenocarcinoma (H295R) cells by inducing channel expression. Endocrinology 2001; 142: 4320-4330.
16. Imagawa K, Okayama S, Takaoka M, et al: Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 2006; 47: 133-138.
17. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29: 493-497.
18. Tsutamoto T, Wada A, Maeda K, et al: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
19. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
20. Cohn JN, Johnson G, Ziesche S, et al: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
21. Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
22. Hayashi M, Tsutamoto T, Wada A, et al: Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826.
23. Hayashi M, Tsutamoto T, Wada A, et al: Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2001; 38: 1375-1382.
24. Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
25. Hayashi M, Tsutamoto T, Wada A, et al: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003; 107: 2559-2565.
26. Rossier MF, Lesouhaitier O, Perrier E, Bockhorn L, Chiappe A, Lalevee N: Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mot Biol 2003; 85: 383-388.
27. Lalevee N, Rebsamen MC, Barrere-Lemaire S, et al: Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 2005; 67: 216-224.
28. Wagner C, Kramer BK, Hinder M, Kieninger M, Kurtz A: T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats. Br J Pharmacol 1998; 124: 579-5 85.
29. Karam H, Clozel JP, Bruneval P, Gonzalez MF, Menard J: Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats. Hypertension 1999; 34: 673-678.
30. Lamarre-Cliche M, de Champlain J, Lacourciere Y, Poirier L, Karas M, Larochelle P: Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. Am J Hypertens 2005; 18: 56-64.
31. Schweda F, Kurtz A: Cellular mechanism of renin release. Acta Physiol Scand 2004; 181: 383-390.
32. Schunkert H, Hense HW, Muscholl. M, et al: Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997; 77: 24-31.
33. Vasan RS, Evans JC, Larson MG, et al: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
34. Kario K, Yasui N, Yokoi H: Ambulatory blood pressure monitoring for cardiovascular medicine. IEEE Eng Med Biol Mag 2003; 22: 81-88.
35. Gillman MW, Kannel WB, Belanger A, D'Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
36. Harada K, Nomura M, Nishikado A, Uehara K, Nakaya Y, Ito S: Clinical efficacy of efonidipine hydrochloride, a T-type calcium channel inhibitor, on sympathetic activities. Circ J 2003; 67: 139-145.
37. 2+ channels in ventricular cells from hypertrophied rat hearts. J Mot Cell Cardiol 1999; 31: 1617-1625.
38. Mulder P, Richard V, Compagnon P, et al: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997; 29: 416-421.
39. 2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 2000; 46: 442-449.
40. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994; 75: 149-155.